Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $8.8 million.

  • Adma Biologics' Other Non-Current Assets rose 5119.44% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 5119.44%. This contributed to the annual value of $5.7 million for FY2024, which is 2113.49% up from last year.
  • Per Adma Biologics' latest filing, its Other Non-Current Assets stood at $8.8 million for Q3 2025, which was up 5119.44% from $9.1 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Other Non-Current Assets registered a high of $9.1 million during Q2 2025, and its lowest value of $2.2 million during Q1 2021.
  • In the last 5 years, Adma Biologics' Other Non-Current Assets had a median value of $4.8 million in 2022 and averaged $5.2 million.
  • The largest annual percentage gain for Adma Biologics' Other Non-Current Assets in the last 5 years was 9304.46% (2021), contrasted with its biggest fall of 3585.43% (2021).
  • Over the past 5 years, Adma Biologics' Other Non-Current Assets (Quarter) stood at $4.1 million in 2021, then increased by 17.27% to $4.8 million in 2022, then fell by 2.1% to $4.7 million in 2023, then increased by 21.13% to $5.7 million in 2024, then surged by 55.52% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $9.1 million for Q2 2025, and $8.2 million during Q1 2025.